231 related articles for article (PubMed ID: 17704250)
1. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
Francis RJ; Byrne MJ; van der Schaaf AA; Boucek JA; Nowak AK; Phillips M; Price R; Patrikeos AP; Musk AW; Millward MJ
J Nucl Med; 2007 Sep; 48(9):1449-58. PubMed ID: 17704250
[TBL] [Abstract][Full Text] [Related]
2. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
Veit-Haibach P; Schaefer NG; Steinert HC; Soyka JD; Seifert B; Stahel RA
Lung Cancer; 2010 Mar; 67(3):311-7. PubMed ID: 19482372
[TBL] [Abstract][Full Text] [Related]
3. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
[TBL] [Abstract][Full Text] [Related]
4. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sharif S; Zahid I; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
Lopci E; Zucali PA; Ceresoli GL; Perrino M; Giordano L; Gianoncelli L; Lorenzi E; Gemelli M; Santoro A; Chiti A
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):667-75. PubMed ID: 25403555
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
[TBL] [Abstract][Full Text] [Related]
8. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
[TBL] [Abstract][Full Text] [Related]
9. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.
Nowak AK; Francis RJ; Phillips MJ; Millward MJ; van der Schaaf AA; Boucek J; Musk AW; McCoy MJ; Segal A; Robins P; Byrne MJ
Clin Cancer Res; 2010 Apr; 16(8):2409-17. PubMed ID: 20371686
[TBL] [Abstract][Full Text] [Related]
10. Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication.
Bille A; Chicklore S; Okiror L; Cook GJ; Spicer J; Landau D; Lang-Lazdunski L
Nucl Med Commun; 2013 Nov; 34(11):1075-83. PubMed ID: 23963351
[TBL] [Abstract][Full Text] [Related]
11. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
Kitajima K; Kuribayashi K; Minami T; Yokoyama H; Nakamura A; Hashimoto M; Kijima T; Hasegawa S; Kaida H; Yamakado K
Oncotarget; 2024 Jun; 15():408-417. PubMed ID: 38900646
[TBL] [Abstract][Full Text] [Related]
12. Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F-FDG PET/CT scan correlation.
Feigen M; Lee ST; Lawford C; Churcher K; Zupan E; Scott AM; Hamilton C
J Med Imaging Radiat Oncol; 2011 Jun; 55(3):320-32. PubMed ID: 21696568
[TBL] [Abstract][Full Text] [Related]
13. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.
Kaira K; Serizawa M; Koh Y; Takahashi T; Hanaoka H; Oriuchi N; Endo M; Kondo H; Nakajima T; Yamamoto N
Eur J Cancer; 2012 May; 48(8):1244-54. PubMed ID: 22330319
[TBL] [Abstract][Full Text] [Related]
14. Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.
Abakay A; Komek H; Abakay O; Palanci Y; Ekici F; Tekbas G; Tanrikulu AC
Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1233-41. PubMed ID: 23690193
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
16. Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.
Tan C; Barrington S; Rankin S; Landau D; Pilling J; Spicer J; Cane P; Lang-Lazdunski L
J Thorac Oncol; 2010 Mar; 5(3):385-8. PubMed ID: 20087231
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
Marin-Oyaga VA; Salavati A; Houshmand S; Pasha AK; Gharavi M; Saboury B; Basu S; Torigian DA; Alavi A
Hell J Nucl Med; 2015; 18(1):11-8. PubMed ID: 25679073
[TBL] [Abstract][Full Text] [Related]
18. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
Francis RJ; Segard T; Morandeau L; Lee YC; Millward MJ; Segal A; Nowak AK
Lung Cancer; 2015 Oct; 90(1):55-60. PubMed ID: 26259878
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness of 18F-FDG PET-CT in the presurgical assessment of malignant pleural mesothelioma treated with neoadjuvant chemotherapy].
Orcajo Rincón J; Alonso Farto JC; Rotger Regi A; Hernández Pérez R; Hualde AM; Pérez Aradas V
Rev Esp Med Nucl; 2011; 30(5):307-10. PubMed ID: 21641092
[TBL] [Abstract][Full Text] [Related]
20. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
Ceresoli GL; Chiti A; Zucali PA; Rodari M; Lutman RF; Salamina S; Incarbone M; Alloisio M; Santoro A
J Clin Oncol; 2006 Oct; 24(28):4587-93. PubMed ID: 17008700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
